LONDON, April 21, 2017 /PRNewswire/ --
Norgine B.V. today presented a new analysis from the UK real world study IMPRESS, that shows treatment with rifaximin-alpha for hepatic encephalopathy could significantly reduce the number of emergency department attendances, with or without admission per patient, at six months of treatment initiation. This effect was sustained at 12 months.
(Logo: http://photos.prnewswire.com/prnh/20130829/633895-a )
This data was sponsored by Norgine and presented at The International Liver Congress on 19-23 April 2017, The Netherlands.
IMPRESS is a retrospective observational study that included 11 specialist National Health Service (NHS) centres with 145 patients prescribed rifaximin-alpha for hepatic encephalopathy. In the study, treatment with rifaximin-alpha for hepatic encephalopathy was well tolerated.
Hepatic encephalopathy is a potentially life-threatening neuropsychiatric condition associated with liver disease. Hepatic encephalopathy affects around 10,000 patients in the UK.
Peter Martin, Chief Operating Officer at Norgine said, "The IMPRESS study continues to reinforce the value of rifaximin-alpha in reducing the recurrence of episodes of hepatic encephalopathy. By recognising hepatic encephalopathy patients and treating them as early as possible with rifaximin-alpha, healthcare systems will make significant savings."
XIFAXAN(R) 550mg / TARGAXAN(R) 550mg / TIXTELLER(R) 550mg (rifaximin-alpha) is reimbursed through healthcare systems in Australia, England and Wales, Germany, Ireland, Italy, Luxembourg, Netherlands, New Zealand, Norway, Scotland, Sweden and Switzerland.
Norgine currently holds marketing rights for XIFAXAN(R) 550mg (known as TARGAXAN(R) 550mg in the UK and Belgium) in Australia, Belgium, Denmark, Finland, Germany, Luxembourg, Netherlands, New Zealand, Norway, Republic of Ireland, Sweden and United Kingdom.
View full release on http://www.norgine.com
1. Hudson. M. et al. Rifaximin-alpha is associated with reductions in emergency department resource use in UK patients with hepatic encephalopathy: real world evidence from the IMPRESS study. Abstract ILC2017-RS-1526. The International Liver Congress, 19-23 April 2017; Amsterdam, The Netherlands.
2. Aspinall R. et al. The impact of rifaximin-alpha on NHS hospital resource use in UK patients with hepatic encephalopathy: a retrospective observational study (IMPRESS). Abstract ILC2016-RS-1132. The International Liver Congress, 13-17 April 2016
3. Patidar KR. et al. Covert hepatic encephalopathy is independently associated with poor survival and increased risk of hospitalization. Am J Gastroenterol. 2014. 109. 1757-63.
4. Fleming K M. et al. Incidence and prevalence of cirrhosis in the United Kingdom, 1992-2001: A general population-based study. Journal of Hepatology 49 (2008) 732-738.
Follow us @norgine